uBriGene Biosciences is a contract development and manufacturing organisation (CDMO) that supports biotechnology and pharmaceutical companies with integrated services spanning research, process and analytical development, regulatory support, and GMP manufacturing for advanced therapeutic products. The company operates globally and offers solutions for a range of modalities, including cell therapies, viral vectors, RNA therapeutics and induced pluripotent stem cell (iPSC) technologies. uBriGene’s infrastructure and technical expertise aim to support programmes from early discovery through to clinical and commercial stages.

Key Products and Services

• Contract Development Services – process design, analytical methods, tech transfer, and regulatory support for ATMP programmes.
• GMP Manufacturing – production of cell and gene therapies, RNA medicines and viral vectors under GMP conditions.
• RNA-LNP Platforms – GMP RNA-LNP manufacturing with controlled batch consistency and high yield.
• Plasmid and Vector Production – preparation of research-grade and GMP-grade plasmids and viral vectors (AAV, LVV, etc.).
• Cell Therapy and iPSC Services – support for CAR-T, TCR-T and other cellular products, including reprogramming and cell banking.

Founded in 2015, uBriGene has established a broad platform to help accelerate translational development for advanced therapies. Its facilities and technical teams are designed to meet regulatory requirements and quality standards in multiple regions. With capabilities that cover early-stage research to late-stage GMP production, uBriGene positions itself as a partner for companies advancing complex therapeutic programmes, including cell and gene therapies and next-generation RNA-based medicines.